跳至主要内容
临床试验/EUCTR2020-004132-22-SE
EUCTR2020-004132-22-SE进行中(未招募)1 期

Double-blind randomized acetazolamide trial in normal pressure hydrocephalus - DRAI

ppsala University Hospital0 个研究点目标入组 56 人开始时间: 2020年11月30日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Diagnosis of idiopathic normal pressure hydrocephalus according to international guidelines
  • •2. Age =50 years and = 82 years
  • •3. Cognitive function with Mini-Mental State Examination > 20 points or cognitive domain of the iNPH scale =30 points
  • •4. MRI image for iNPH defined as callosal angle <95 degrees and dilated lateral ventricles or image as in disproportionately subarachnoid space hydrocephalus (DESH)
  • •5. Signed informed consent form
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 56

排除标准

  • •1. Exclusion criteria for MRI examination
  • •2. Participation in another medical trial
  • •3. Other disease likely to impact the symptoms of the patient
  • •4. Wheelchair bound or in need of support when walking
  • •5. Reduced kidney function with creatinine GFR < 50
  • •6. Reduced liver function: Prothrombin complex > 1.2 or increased alanine transaminase concentrations in plasma 1.5 times above the upper reference value (women > 1.125 mkat/L; men > 1.65 mkat/L).
  • •7. Known heart failure
  • •8. Low concentrations of electrolytes in blood plasma, or other illness or treatment that may cause significant lowering of electrolyte concentrations according to the investigator
  • •9. Angle-closure glaucoma
  • •10. Allergy to acetazolamide, sulfonamides, or sulfonamide derivatives
  • •11. Treatment with phenytoin, valproate, carbamazepine, lithium, thiazide-diuretics > 25mg/day, acetylsalicylic acid > 100 mg/day, daily use of NSAID or furosemide > 20 mg/day
  • •12. Inability to swallow capsules of the same size as the investigational medicinal products (will be tested using empty capsules when the patient is asked to participate in the study)
  • •13. Average walking time for the three walking tests <10.5 seconds for men and <11.5 seconds for women
  • •14. Average walking time for the three walking tests > 50 seconds
  • •15. Inability to comply with the study treatment independently, and a concurrent lack of individuals to help the patient comply with the treatment during the study period
  • •16. Females who are not infertile or females of childbearing potential who do not use highly effective birth control. For females of childbearing potential a negative pregnancy test will be documented before inclusion

研究者

发起方
ppsala University Hospital

相似试验